COVID-19 Vaccine - en | Covid19.go.id

About COVID-19 Vaccine

Lawan Covid19

What is Vaccination

Vaccination is the administration of vaccines in order to actively generate or increase a person's immunity against a disease, so that if one day they are exposed to the disease, they will not get sick or only experience mild illness and will not become a source of transmission.

COVID-19 vaccination services are carried out at Health Service Facilities owned by the Central Government, Provincial Governments, Regency/City Governments or owned by the public/private sector that meet the requirements, including:

  • Puskesmas, Puskesmas Pembantu
  • Clinic
  • Hospital and/or
  • Health Service Unit at the Port Health Office (KKP)
Or Check Here
District/City Health Offices and Puskesmas can also establish COVID-19 vaccination service posts. It is recommended that each target seek information in advance regarding the service schedule of each health service facility or vaccination service post.

How can Vaccines work in the body to protect us?

  • Vaccines are biological products that are given to a person to protect him or her from a debilitating, even life-threatening disease.
  • Vaccines will stimulate the formation of immunity against certain diseases in a person's body.
  • The body will remember the virus or disease-causing bacteria, recognize and know how to fight it.
Lawan Covid19

List of COVID-19 Vaccines Used in Indonesia

In the implementation of the COVID-19 vaccination program in Indonesia, the government strives for the availability of vaccines to be fulfilled for at least 208,265,720 of the population to achieve group immunity.

These vaccine procurement efforts are carried out through bilateral agreements and multilateral agreements such as the COVAX Facility with GAVI and WHO, or donations provided by friendly countries.

The Indonesian Food and Drug Administration has granted emergency use permits for 10 types of COVID-19 vaccines, namely Sinovac, AstraZeneca, Sinopharm, Moderna, Pfizer, Novavax, Sputnik-V, Janssen, Convidencia, and Zifivax.

Each of these types of vaccines has a mechanism for its own administration, from the number of doses, the interval of administration, to different vaccine platforms, namely inactivated virus, RNA-based, viral-vector, and protein sub-units.

*The vaccines provided are vaccines that have been confirmed to be safe and effective.

SINOVAC VACCINE
COVID-19 Vaccine (Vero Cell) Inactivated, CoronaVac® is an inactivated vaccine against COVID-19 that stimulates the immune system without the risk of causing disease. Once this inactivated vaccine comes into contact with the immune system, antibody production is stimulated, so the body is ready to respond to infection with live SARS-CoV-2. This vaccine contains an adjuvant (aluminum hydroxide), to strengthen the immune system response.
The ChAdOx1-S/nCoV-19 vaccine is a non-replicating adenovirus vector vaccine for COVID-19. The vaccine expresses the SARS-CoV-2 spike protein gene, which instructs the host cell to produce an S-antigen protein unique to SARS-CoV-2, so that the body can generate an immune response and store that information in memory immune cells. Efficacy in clinical trials in participants who received the full course of the vaccine (two doses) in the UK, Brazil, and South Africa regardless of the dose interval was 61%, with a median follow-up period of 80 days, but tends to be higher if this interval is longer. . Additional data from interim analyzes of clinical trials in the United States showed a vaccine efficacy of 76% against symptomatic SARS-CoV-2 infection.
Moderna's COVID-19 vaccine is a messenger RNA (mRNA) based vaccine for COVID-19. The host cell receives instructions from the mRNA to produce the unique S-antigen protein SARS-CoV-2, so that the body can generate an immune response and store that information in memory immune cells. Efficacy according to clinical trials in participants who received the full dose of this vaccine (two doses) and had an initial SARS-CoV-2 negative status was approximately 94% with a median follow-up period of nine weeks. All data reviewed support the conclusion that the known and potential benefits of the mRNA-1273 vaccine outweigh the known and potential risks.
The SARS-CoV-2 Vaccine (Vero Cell) is an inactivated vaccine against COVID-19 that stimulates the immune system without the risk of causing disease. Once this inactivated vaccine comes into contact with the immune system, antibody production is stimulated, so the body is ready to respond to infection with live SARS-CoV-2. This vaccine contains an adjuvant (aluminum hydroxide), to strengthen the immune system response. A large phase 3 clinical trial demonstrated that two doses at 21-day intervals had 79% efficacy against symptomatic SARS-CoV-2 infection 14 days or more after the second dose. These clinical trials are neither designed nor robust enough to demonstrate efficacy against severe disease.
COMIRNATY® is a messenger RNA (mRNA) based vaccine for COVID-19. The mRNA instructs the cell to produce an S-antigen protein (part of the spike protein) unique to SARS-CoV-2 to stimulate an immune response. In clinical trials, efficacy in participants with or without evidence of previous SARS-CoV-2 infection and who received the full dose of this vaccine (two doses) was estimated at 95% with a median follow-up period of two months.

Question and Answer

a. Targets who drop out in less than six months can be given a second vaccine with a different type of vaccine according to availability in each region.

b. For targets who drop out within more than six months, the primary vaccination is resumed 2 times and the vaccination can use a different type of vaccine from the original vaccine.

c. Considering that currently the number of Sinovac vaccines that are distributed is limited and is intended for children aged 6-11 years, those who drop out can use different types of vaccines and are available to complete the second dose by prioritizing vaccines that have the closest expiration date.

Immediately complete the booster dose by coming to the nearest health facility. Check the nearest health facility at https://covid19.go.id/faskesvaksin

Ministry of Health data shows that 70% of the 8,230 patients who died from COVID-19 had not received full vaccination.

This proves that complete and booster vaccination can reduce the risk of hospitalization and death. Come on, protect ourselves and the people around us, immediately vaccinate when it's our turn.

Booster vaccination can increase immunity up to 2x compared to the second dose of vaccination.

Boosters can protect the elderly and vulnerable/comorbid community groups from COVID-19 transmission.

Currently the stock of the COVID-19 vaccine for boosters is more than enough, let's hurry to get a booster if it's your turn.

Free booster vaccine for all community.

source: Kemenkes

You can get a booster vaccine after 3 months of getting a second dose of vaccine. Vaccination schedules and tickets will appear in the PeduliLindungi application under the "Vaccination Status & Covid-19 Test Results" menu.

Important Info